» Articles » PMID: 24171032

Mediators of Inflammation and Their Effect on Resident Renal Cells: Implications in Lupus Nephritis

Overview
Date 2013 Oct 31
PMID 24171032
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Lupus nephritis affects up to 70% of patients with systemic lupus erythematosus and is a major cause of morbidity and mortality. It is characterized by a breakdown of immune tolerance, production of autoantibodies, and deposition of immune complexes within the kidney parenchyma, resulting in local inflammation and subsequent organ damage. To date, numerous mediators of inflammation have been implicated in the development and progression of lupus nephritis, and these include cytokines, chemokines, and glycosaminoglycans. Of these, type I interferons (IFNs) can increase both gene and protein expression of cytokines and chemokines associated with lupus susceptibility, and interleukin-6 (IL-6), tumor necrosis factor- α (TNF- α ) and hyaluronan have been shown to elicit both pro- and anti-inflammatory effects on infiltrating and resident renal cells depending on the status of their microenvironment. Expression of IL-6, TNF- α , type I IFNs, and hyaluronan are increased in the kidneys of patients and mice with active lupus nephritis and have been shown to contribute to disease pathogenesis. There is also evidence that despite clinical remission, ongoing inflammatory processes may occur within the glomerular and tubulointerstitial compartments of the kidney, which further promote kidney injury. In this review, we provide an overview of the synthesis and putative roles of IL-6, TNF- α , IFN- α , and hyaluronan in the pathogenesis of lupus nephritis focusing on their effects on human mesangial cells and proximal renal tubular epithelial cells.

Citing Articles

FGF23-related hypophosphatemic rickets preceding the onset of systemic lupus erythematosus: A juvenile case.

Tabei Y, Ohtsu Y, Shimada M, Wada A, Hamajima E, Osawa Y Clin Case Rep. 2024; 12(1):e8420.

PMID: 38223518 PMC: 10784849. DOI: 10.1002/ccr3.8420.


Decipher the Immunopathological Mechanisms and Set Up Potential Therapeutic Strategies for Patients with Lupus Nephritis.

Tsai C, Li K, Shen C, Lu C, Lee H, Wu T Int J Mol Sci. 2023; 24(12).

PMID: 37373215 PMC: 10298725. DOI: 10.3390/ijms241210066.


Mesangial cell: A hub in lupus nephritis.

Liu M, Zhang L, Wang Y, Hu W, Wang C, Wen Z Front Immunol. 2023; 13:1063497.

PMID: 36591251 PMC: 9795068. DOI: 10.3389/fimmu.2022.1063497.


1,4-Disubstituted 1-1,2,3-Triazoles for Renal Diseases: Studies of Viability, Anti-Inflammatory, and Antioxidant Activities.

Cheng C, Haque A, Hsieh M, Hassan S, Faizi M, Dege N Int J Mol Sci. 2020; 21(11).

PMID: 32481556 PMC: 7312092. DOI: 10.3390/ijms21113823.


α2AP is associated with the development of lupus nephritis through the regulation of plasmin inhibition and inflammatory responses.

Kanno Y, Miyashita M, Seishima M, Matsuo O Immun Inflamm Dis. 2020; 8(3):267-278.

PMID: 32237065 PMC: 7416015. DOI: 10.1002/iid3.302.


References
1.
Flur K, Allam R, Zecher D, Kulkarni O, Lichtnekert J, Schwarz M . Viral RNA induces type I interferon-dependent cytokine release and cell death in mesangial cells via melanoma-differentiation-associated gene-5: Implications for viral infection-associated glomerulonephritis. Am J Pathol. 2009; 175(5):2014-22. PMC: 2774065. DOI: 10.2353/ajpath.2009.080585. View

2.
Liu Z, Bethunaickan R, Huang W, Ramanujam M, Madaio M, Davidson A . IFN-α confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice. J Immunol. 2011; 187(3):1506-13. PMC: 3140572. DOI: 10.4049/jimmunol.1004142. View

3.
Neng Lai K, Leung J, Bik Lai K, Li P, Lai C . Anti-DNA autoantibodies stimulate the release of interleukin-1 and interleukin-6 from endothelial cells. J Pathol. 1996; 178(4):451-7. View

4.
Vlahakos D, Foster M, Ucci A, Barrett K, Datta S, Madaio M . Murine monoclonal anti-DNA antibodies penetrate cells, bind to nuclei, and induce glomerular proliferation and proteinuria in vivo. J Am Soc Nephrol. 1992; 2(8):1345-54. DOI: 10.1681/ASN.V281345. View

5.
Laurent T, Fraser J . Hyaluronan. FASEB J. 1992; 6(7):2397-404. View